Delaware
|
001-01136
|
22-0790350
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S Employer
Identification No.)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.10 Par Value
|
BMY
|
New York Stock Exchange
|
1.000% Notes due 2025
|
BMY25
|
New York Stock Exchange
|
1.750% Notes due 2035
|
BMY35
|
New York Stock Exchange
|
Bristol-Myers Squibb Contingent Value Rights
|
BMY RT
|
New York Stock Exchange
|
Celgene Contingent Value Rights
|
CELG RT
|
New York Stock Exchange
|
Item 8.01
|
Other Events.
|
BRISTOL-MYERS SQUIBB COMPANY
|
||
Dated: March 9, 2020
|
By:
|
/s/ Katherine R. Kelly
|
Name:
|
Katherine R. Kelly
|
|
Title:
|
Corporate Secretary
|